RET and T-cell non-Hodgkin lymphoma: With this aim, and aware that the inhibition of RET has always been a challenge since its discovery in T-cell lymphoma [1], we want to summarize the available knowledge on RET inhibitors, including both ongoing trials with new drugs and pre-clinical data concerning overcoming the resistance mechanisms.